Evidence map›Paper›PMID 35928081›Full record

ArticleJournal of obstetrics and gynaecology of India2022

Uterine Sarcoma: Retrospective Study From A Single institute.

S Suchetha, T Vijayashanti, P Rema, J Sivaranjith, Aswin Kumar, K M Jagathnath Krishna, Francis V James

Abstract read
In one paragraph

Article in Journal of obstetrics and gynaecology of India, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S SuchethaDivision of Gynaecologic Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.ORCID 0000-0001-8128-0363
T VijayashantiDivision of Gynaecologic Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.
P RemaDivision of Gynaecologic Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.
J SivaranjithDivision of Surgical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.
Aswin KumarDivision of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.
K M Jagathnath KrishnaDivision of Cancer Epidemiology& Biostatistics, Regional Cancer Centre, Thiruvananthapuram, Kerala India.
Francis V JamesDivision of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract: Uterine sarcomas are heterogeneous group of tumours comprising 1% of gynaecological malignancies. There is lack of concences on optimal treatment of uterine sarcomas. This is because of lack of randomised controlled trials due to rarity of these tumours. Surgical management without spill remains the standard primary treatment. Most of the times uterine sarcomas are diagnosed postoperatively from histopathology report of either myomectomy or hysterectomy. This retrospective study analysed the clinico pathological characteristics, prognostic factors, treatment details and survival outcome of different types of uterine sarcomas. Materials and methods: This is a retrospective analysis of 59 patients of uterine sarcomas. All patients underwent surgery. Adjuvant chemotherapy or radiation treatment were given according to histopathological report and FIGO stage. Patients were followed up every three months for first two years and then every six months. Disease free survival (DFS) and Overall survival (OS) were calculated. Statistical analysis: The data were summarized using descriptive statistics as mean, percent and range. Survival probabilities were estimated using Kaplan-Meier method and the significance of difference between the survival curves were calculate using log-rank test. Results: Uterine sarcomas are rare and aggressive tumours of uterus. Majority of these tumours present in early stage. Surgery remains the main treatment modality. Role of adjuvant radiation treatment remains controversial. Tumour stage is the most important prognostic factor.

Indexed as

Adjuvant chemotherapyLeiomyosarcomaRadiation treatmentStromal sarcomaUterine Sarcoma

Identifiers

PMID35928081
PMCPMC9343530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.